SELLAS GPS Trial Cuts Death Risk 41% as Company Launches $150M Offer
A TradingView analysis says SELLAS's GPS vaccine delivered 24.0 months of median survival in Phase 3, but a $150 million offering, 2026 patent expiries and Shanghai-based supply test the bet.
